Paper42004157
Real-World Treatment Patterns in Patients with Atopic Dermatitis Initiating Ruxolitinib Cream: A 12-Month Follow-Up Analysis of a US Payer Claims Database.
Liu J and 6 others. Clinicoecon Outcomes Res, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Real-World Treatment Patterns in Patients with Atopic Dermatitis Initiating Ruxolitinib Cream: A 12-Month Follow-Up Analysis of a US Payer Claims Database. Papers, record 42004157. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42004157
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Real-World Treatment Patterns in Patients with Atopic Dermatitis Initiating Ruxolitinib Cream: A 12-Month Follow-Up Analysis of a US Payer Claims Database.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33421555 | Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. | Ann Allergy Asthma Immunol | 2021 | https://conductscience.org/library/papers/33421555 | PubMed |
| 2 | 37943240 | Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. | J Am Acad Dermatol | 2024 | https://conductscience.org/library/papers/37943240 | PubMed |
| 3 | 23452057 | Characterization of different courses of atopic dermatitis in adolescent and adult patients. | Allergy | 2013 | https://conductscience.org/library/papers/23452057 | PubMed |
| 4 | 39931253 | Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database. | Clinicoecon Outcomes Res | 2025 | https://conductscience.org/library/papers/39931253 | PubMed |
| 5 | 36641009 | Guidelines of care for the management of atopic dermatitis in adults with topical therapies. | J Am Acad Dermatol | 2023 | https://conductscience.org/library/papers/36641009 | PubMed |
| 6 | 37830436 | Clinically relevant improvements in adults and adolescents with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success following 8 weeks of ruxolitinib cream monotherapy. | J Dermatol | 2023 | https://conductscience.org/library/papers/37830436 | PubMed |
| 7 | 38297490 | Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies. | J Dermatolog Treat | 2024 | https://conductscience.org/library/papers/38297490 | PubMed |
| 8 | 36066323 | Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. | J Eur Acad Dermatol Venereol | 2023 | https://conductscience.org/library/papers/36066323 | PubMed |
| 9 | 38243107 | Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year. | Am J Clin Dermatol | 2024 | https://conductscience.org/library/papers/38243107 | PubMed |
| 10 | 36264430 | Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies. | Am J Clin Dermatol | 2023 | https://conductscience.org/library/papers/36264430 | PubMed |
| 11 | 30389491 | Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. | J Invest Dermatol | 2019 | https://conductscience.org/library/papers/30389491 | PubMed |
| 12 | 36095314 | Development and Validation of the Summary Elixhauser Comorbidity Score for Use With ICD-10-CM-Coded Data Among Older Adults. | Ann Intern Med | 2022 | https://conductscience.org/library/papers/36095314 | PubMed |
| 13 | 36574595 | Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies. | J Am Acad Dermatol | 2023 | https://conductscience.org/library/papers/36574595 | PubMed |
| 14 | 39760983 | A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis. | Am J Clin Dermatol | 2025 | https://conductscience.org/library/papers/39760983 | PubMed |
| 15 | 33957195 | Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. | J Am Acad Dermatol | 2021 | https://conductscience.org/library/papers/33957195 | PubMed |
| 16 | 39707983 | Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024. | Expert Opin Drug Saf | 2026 | https://conductscience.org/library/papers/39707983 | PubMed |
| 17 | 36197589 | Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review. | Dermatol Ther (Heidelb) | 2022 | https://conductscience.org/library/papers/36197589 | PubMed |
| 18 | 30417330 | Atopic dermatitis: the relationship to temperature and seasonality in the United States. | Int J Dermatol | 2019 | https://conductscience.org/library/papers/30417330 | PubMed |
| 19 | 39375281 | Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History. | Dermatol Ther (Heidelb) | 2024 | https://conductscience.org/library/papers/39375281 | PubMed |
| 20 | 30025911 | Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. | Ann Allergy Asthma Immunol | 2018 | https://conductscience.org/library/papers/30025911 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42554948 | Real-World Effect of Ruxolitinib Cream: Decreased Use of Additional Topical Therapies and Limited Escalation to Systemic Treatments. | Adv Ther | 2026 | https://conductscience.org/library/papers/42554948 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42004157
GET https://conductscience.org/api/papers/v1/42004157/references?page=2